CB Insights September 3, 2020
Global funding to private genomics companies has boomed over the past decade, with funding up more than 6x in 2019 compared to 2013. Now, there are signs that the market may be maturing, as investors cut bigger checks to more established players.
In the last couple of years, there’s been a notable rise in investment to genomics companies located outside the US, as startups seek to improve genetic data diversity. Demand for Covid-19 genetic tests has further accelerated the funding trend, with total global funding to private genomics companies projected to reach over $4.4B in 2020.
We define genomics to include companies involved in the capture, sequencing, and/or analysis of genetic data, such as personal genetics company 23andMe...
Today's Sponsors
Today's Sponsor